| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Trial |
The efficacy and tolerability of salmeterol, 50 micrograms b.i.d. was compared for three months with salbutamol, 200 micrograms q.i.d., administered from metered-dose inhaler. For the following nine months, safety and clinic lung function was monitored on salmeterol, 50 micrograms b.i.d., compared with salbutamol, 200 micrograms b.i.d. This comparison was made in a multicentre, double-blind, parallel-group study of 667 moderate asthmatics, who had a forced expiratory volume in one second (FEV1) or peak expiratory flow rate (PEFR) > 50% predicted, a 15% reversibility to inhaled salbutamol and who were experiencing symptoms. Throughout the first three month treatment period, both morning and evening PEFR were significantly higher on treatment with salmeterol than salbutamol (mean differences between the treatments 30 l.min-1 for morning, p < 0.001, and 11 l.min-1 for evening, p < 0.01). In addition, the diurnal variation in PEFR, nocturnal and daytime symptoms and use of additional salbutamol were significantly lower in the salmeterol treated group. This improvement was also apparent in the separate subpopulations of patients taking no concurrent glucocorticosteroid or concurrent inhaled and/or oral glucocorticosteroids. Both treatments were well-tolerated throughout the 12 months of treatment. There was a lower incidence of asthma and related events during salmeterol treatment compared to salbutamol treatment subgroups. The results of the study clearly demonstrate that salmeterol, 50 micrograms b.i.d., is well-tolerated and more effective than salbutamol, 200 micrograms q.i.d., in the treatment of moderate asthma.
This article has been cited by other articles:
|
|
 |
|
  R. H. Moore, E. E. Millman, V. Godines, N. A. Hanania, T. M. Tran, H. Peng, B. F. Dickey, B. J. Knoll, and R. B. Clark Salmeterol Stimulation Dissociates beta2-Adrenergic Receptor Phosphorylation and Internalization Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 254 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. D'Urzo, K. R. Chapman, A. Cartier, F. E. Hargreave, M. Fitzgerald, and D. Tesarowski Effectiveness and Safety of Salmeterol in Nonspecialist Practice Settings Chest, March 1, 2001; 119(3): 714 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Peters, D. C. Shelledy, A. P. Jones Jr., R. W. Lawson, C. P. Davis, and T. S. LeGrand A Randomized, Placebo-Controlled Study To Evaluate the Role of Salmeterol in the In-Hospital Management of Asthma Chest, August 1, 2000; 118(2): 313 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Demirkan, E. Tolley, T. Mastin, J. Soberman, J. Burbeck, and T. Self Salmeterol Administration by Metered-Dose Inhaler Alone vs Metered-Dose Inhaler Plus Valved Holding Chamber Chest, May 1, 2000; 117(5): 1314 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]
|
|
|
|
|
|
G. SHAPIRO, W. LUMRY, J. WOLFE, J. GIVEN, M. V. WHITE, A. WOODRING, L. BAITINGER, K. HOUSE, B. PRILLAMAN, and T. SHAH Combined Salmeterol 50 {micro}g and Fluticasone Propionate 250 {micro}g in the Diskus Device for the Treatment of Asthma Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 527 - 534. [Abstract] [Full Text]
|
|
|
|
|
|
R. R. Rosenthal, W. W. Busse, J. P. Kemp, J. W. Baker, C. Kalberg, A. Emmett, and K. A. Rickard Effect of Long-term Salmeterol Therapy Compared With As-Needed Albuterol Use on Airway Hyperresponsiveness Chest, September 1, 1999; 116(3): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. NELSON, R. B. BERKOWITZ, D. A. TINKELMAN, A. H. EMMETT, K. A. RICKARD, and S. W. YANCEY Lack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1556 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Giannini, E. Bacci, F. L. Dente, A. Di Franco, B. Vagaggini, R. Testi, and P. Paggiaro Inhaled Beclomethasone Dipropionate Reverts Tolerance to the Protective Effect of Salmeterol on Allergen Challenge Chest, March 1, 1999; 115(3): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chervinsky, P. Goldberg, S. Galant, Y. Wang, T. Arledge, M. B. Welch, and E. Stahl Long-term Cardiovascular Safety of Salmeterol Powder Pharmacotherapy in Adolescent and Adult Patients With Chronic Persistent Asthma: A Randomized Clinical Trial Chest, March 1, 1999; 115(3): 642 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Lockey, L. M. DuBuske, B. Friedman, V. Petrocella, F. Cox, and K. Rickard Nocturnal Asthma: Effect of Salmeterol on Quality of Life and Clinical Outcomes Chest, March 1, 1999; 115(3): 666 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A van Noord, A J M Schreurs, S J M Mol, and P G H Mulder Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma Thorax, March 1, 1999; 54(3): 207 - 212. [Abstract] [Full Text]
|
|
|
|
|
|
A. A. P. H. VERBERNE, C. FROST, E. J. DUIVERMAN, M. H. GROL, K. F. KERREBIJN, and the Dutch Paediatric Asthma Study Group Addition of Salmeterol versus Doubling the Dose of Beclomethasone in Children with Asthma Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 213 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Pauwels, C.-G. Lofdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes, A. Ullman, and The Formoterol and Corticosteroids Establishing Th Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma N. Engl. J. Med., November 13, 1997; 337(20): 1405 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. M. WEERSINK, E. H. van ZOMEREN, G. H. KOETER, and D. S. POSTMA Treatment of Nocturnal Airway Obstruction Improves Daytime Cognitive Performance in Asthmatics Am. J. Respir. Crit. Care Med., October 1, 1997; 156(4): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of asthma in adults BMJ, March 23, 1996; 312(7033): 762 - 766. [Full Text]
|
|
|
|
|
|
H. S. Nelson {beta}-Adrenergic Bronchodilators N. Engl. J. Med., August 24, 1995; 333(8): 499 - 507. [Full Text] [PDF]
|
|
|
|
|
|
R W Fuller Controversies in Management: Adverse effects are not proved BMJ, September 24, 1994; 309(6957): 795 - 796. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
